<!DOCTYPE html><html lang="en"><head><meta name="generator" content="Scully 0.0.0">
  <meta charset="utf-8">
  <title>NgxGardSkully 123</title>
  <base href="/">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <link rel="icon" type="image/x-icon" href="favicon.ico">
<link rel="stylesheet" href="styles.4cdd1989b7928c8b693d.css"><style>body,html{overflow-x:hidden}@media (max-width:991.98px){.offcanvas-collapse{position:fixed;top:56px;bottom:0;left:100%;width:100%;padding-right:1rem;padding-left:1rem;overflow-y:auto;visibility:hidden;background-color:#343a40;transition:transform .3s ease-in-out,visibility .3s ease-in-out}.offcanvas-collapse.open{visibility:visible;transform:translateX(-100%)}}.nav-scroller{position:relative;z-index:2;height:2.75rem;overflow-y:hidden}.nav-scroller .nav{display:flex;flex-wrap:nowrap;padding-bottom:1rem;margin-top:-1px;overflow-x:auto;color:hsla(0,0%,100%,.75);text-align:center;white-space:nowrap;-webkit-overflow-scrolling:touch}.nav-underline .nav-link{padding-top:.75rem;padding-bottom:.75rem;font-size:.875rem;color:#6c757d}.nav-underline .nav-link:hover{color:#007bff}.nav-underline .active{font-weight:500;color:#343a40}.text-white-50{color:hsla(0,0%,100%,.5)}.bg-purple{background-color:#6f42c1}.lh-100{line-height:1}.lh-125{line-height:1.25}.lh-150{line-height:1.5}.splitter{margin-left:20px;margin-right:20px;display:inline-block;font-size:20px;transform:scaleX(.3)}.banner{background-color:#1b5b76;height:116px;background-image:url(https://rarediseases.info.nih.gov/content/images/banner-touch-diseases.jpg);background-repeat:no-repeat;background-position:100%}.search-ct{top:40px;left:30px}.footer{background:#d3d3d3;height:230px}.footer-links{padding-top:20px}.footer-text{margin-top:30px;text-align:center}.input-group-text{cursor:pointer}</style><style></style><script>window['ScullyIO']='generated';</script></head>
<body scully-version="0.0.0">
  <app-root ng-version="10.0.14"><nav class="navbar navbar-dark sticky-top bg-dark flex-md-nowrap p-0 shadow"><span class="shrink-width"><ul class="navbar-nav px-3 list-inline"><li class="nav-item text-nowrap list-inline-item"><span href="#" class="nav-link">U.S. Department of Health &amp; Human Services <span class="splitter"> &gt; </span> National Institutes of Health <span class="splitter"> &gt; </span> NCATS</span></li></ul></span></nav><div class="shrink-width"><div class="nav-scroller bg-white shadow-sm justify-content-center"><nav class="nav nav-underline"><a routerlink="/diseases" routerlinkactive="active" class="nav-link active" href="/diseases">Diseases</a><a routerlink="/help" routerlinkactive="active" class="nav-link" href="/help">Guides</a><a routerlink="/news" routerlinkactive="active" class="nav-link" href="/news">News</a><a routerlink="/about" routerlinkactive="active" class="nav-link" href="/about">About GARD</a><a routerlink="/espanol" routerlinkactive="active" class="nav-link" href="/espanol">En Espanõl</a></nav></div><form novalidate="" class="ng-untouched ng-pristine ng-valid"><div class="banner"><div class="col-md-6 search-ct"><div class="input-group mb-3"><input formcontrolname="search" type="text" placeholder="Search for Diseases, Organizations, News and More..." aria-label="Search for Diseases, Organizations, News and More..." aria-describedby="basic-addon2" class="form-control ng-untouched ng-pristine ng-valid"><span class="input-group-text">GO</span></div></div></div></form><div class="container-fluid"><router-outlet></router-outlet><app-disease-details><div class="row"><div class="col-md-3"><nav><div class="sidebar-sticky pt-3"><ul class="nav flex-column"><li class="nav-item"><a routerlink="/diseases" routerlinkactive="active" class="nav-link active" href="/diseases"> Browse A-Z </a></li><li class="nav-item"><a routerlink="/diseases" routerlinkactive="active" class="nav-link active" href="/diseases"> Find Diseases By Category </a></li><li class="nav-item"><a routerlink="/diseases" routerlinkactive="active" class="nav-link active" href="/diseases"> List of FDA Orphan Drugs </a></li><li class="nav-item"><a routerlink="/diseases" routerlinkactive="active" class="nav-link active" href="/diseases"> GARD Information Navigator </a></li><li class="nav-item"><a routerlink="/diseases" routerlinkactive="active" class="nav-link active" href="/diseases"> FAQs About Rare Diseases </a></li></ul></div></nav></div><main role="main" class="col-md-9"><div class="d-flex justify-content-between flex-wrap flex-md-nowrap align-items-center pt-3 pb-2 mb-3 border-bottom"><h1 class="h2">Disease # 3126 - Familial partial lipodystrophy type 2</h1></div><div><p><b>Other Names: </b>FPLD2, Lipodystrophy, familial partial, Dunnigan type, Lipodystrophy, familial, of limbs and lower trunk, Lipodystrophy, reverse partial, Lipoatrophic diabetes, FPL2, Lipodystrophy, familial partial, type 2, Dunnigan syndrome, Familial partial lipodystrophy, Dunnigan type</p><p><b>Categories: </b><span> Congenital and Genetic Diseases</span><span> Endocrine Diseases</span><span> Metabolic disorders</span><span> Skin Diseases</span><!----></p><p><b>This disease is grouped under: </b>Familial partial lipodystrophy</p><p><b>Summary: </b><span><strong>Familial partial lipodystrophy type 2</strong>&nbsp;(FPLD2) is a rare, genetic disorder that affects the amount and distribution of fat (adipose tissue) in the body. Symptoms typically develop around puberty, after having normal adipose tissue in childhood.[14994] FPLD2 causes a loss of adipose tissue from the limbs, torso, buttocks and hips, while causing a buildup of adipose tissue in the face, neck, and upper back.[14994][11802][11803][11804] It may also cause increased musculature.[11802] Some people with FPLD2 have areas of dark, thick skin (<a href="https://www.aad.org/public/diseases/color-problems/acanthosis-nigricans" target="_blank">acanthosis nigricans</a>), and females may have excessive hairiness (<a href="https://www.aad.org/public/diseases/color-problems/acanthosis-nigricans" target="_blank">hirsutism</a>)&nbsp;and menstrual abnormalities.[14994] <a href="https://medlineplus.gov/metabolicdisorders.html" target="_blank">Metabolic abnormalities</a>&nbsp;develop in adolescence or adulthood, leading to signs and symptoms that may include&nbsp;<a href="http://www.niddk.nih.gov/health-information/health-topics/Diabetes/insulin-resistance-prediabetes/Pages/index.aspx" target="_blank">insulin resistance</a>, <a href="https://www.merckmanuals.com/home/hormonal-and-metabolic-disorders/cholesterol-disorders/dyslipidemia" target="_blank">dyslipidemia</a>, diabetes, <a href="https://www.niddk.nih.gov/health-information/digestive-diseases/pancreatitis" target="_blank">pancreatitis</a> (or recurrent acute pancreatitis),&nbsp;<a href="https://www.nlm.nih.gov/medlineplus/ency/article/007657.htm" target="_blank">liver steatosis</a>, atherosclerosis, and an increased risk of heart disease.[11802][11803]<br>
<br>
FPLD2 is caused by <a href="http://www.genome.gov/Glossary/index.cfm?id=134" target="_blank">mutations</a>&nbsp;in the <em><a href="https://ghr.nlm.nih.gov/gene/LMNA" target="_blank">LMNA</a></em> gene and inheritance is autosomal dominant.[11802][11803][11804] Treatment aims to correct metabolic abnormalities and manage complications. This may involve medications, monitoring the diet, and exercise.[11802] Plastic surgery may be considered by some individuals.[11802] People with FPL2 are encouraged to seek counseling and support after being diagnosed, as the disorder can cause anxiety and psychological distress.[11803] The long-term health outlook generally depends on the severity of complications such as diabetes, pancreatitis, and heart disease.[11802]</span></p><div><b>Organizations: </b><ul><li><span><a href="org.url">Metabolic Support UK</a></span><br><span>5 Hilliards Court</span><br><span>Chester , CH4 9QP</span><br><!----><!----></li><li><span><a href="org.url">American Dietetic Association</a></span><br><span>120 South Riverside Plaza, Suite 2000</span><br><span>Chicago IL, 60606-6995</span><br><!----><!----></li><li><span><a href="org.url">Lipodystrophy United</a></span><br><span>22 Frances Road</span><br><span>Los Lunas NM, 87031</span><br><!----><!----></li><!----></ul></div><div><b>Learn More</b><ul><li><span><a href="http://www.omim.org/151660" target="_blank">Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br>
</span></li><li><span><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=omim&amp;cmd=Display&amp;dopt=omim_pubmed_calculated&amp;from_uid=151660" target="_blank">PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Familial partial lipodystrophy type 2. Click on the link to view a sample search on this topic.</span></li><li><span><a href="https://clinicaltrials.gov/ct2/results?term=partial+lipodystrophy&amp;Search=Search " target="_blank">ClinicalTrials.gov</a> lists trials that are related to Familial partial lipodystrophy type 2. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br>
<br>
<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em></span></li><li><span><a href="https://ghr.nlm.nih.gov/condition/familial-partial-lipodystrophy" target="_blank">Genetics Home Reference (GHR)</a> contains information on Familial partial lipodystrophy type 2. This website is maintained by the National Library of Medicine.<br>
</span></li><li><span>To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href="http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx" target="_blank">American College of Medical Genetics</a> and the&nbsp;<a href="https://www.findageneticcounselor.com/" target="_blank">National Society of Genetic Counselors</a>. If you need additional help, <a href="https://rarediseases.info.nih.gov/about-gard/contact-gard">contact a GARD Information Specialist</a>. You can also&nbsp;<a href="https://ghr.nlm.nih.gov/primer#consult" target="_blank">learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.</span></li><li><span>The <a href="http://www.ncbi.nlm.nih.gov/gtr/conditions/C1720860" target="_blank">Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br>
</span></li><li><span>The <a href="http://rarediseases.org/rare-diseases/familial-partial-lipodystrophy/ " target="_blank">National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br>
</span></li><li><span><a href="http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&amp;Expert=2348" target="_blank">Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br>
</span></li><li><span>The <a href="https://rarediseases.org/physician-guide/lipodystrophy-disorders/" target="_blank">NORD Physician Guide</a> for Familial partial lipodystrophy type 2 was developed as a free service of the National Organization for Rare Disorders (NORD) and it's medical advisors. &nbsp;The guides provide a resource for clinicians about specific rare disorders to facilitate diagnosis and treatment of their patients with this condition.&nbsp;</span></li><li><span>The <a href="https://monarchinitiative.org/disease/OMIM:151660" target="_blank">Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch’s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.</span></li><li><span>Krawiec P, Melges B, Pac-Kozuchowska E, Mroczkowska-Juchkiewicz A, Czerska K.&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790055/" target="_blank">Fitting the pieces of the puzzle together: a case report of the Dunnigan-type of familial partial lipodystrophy in the adolescent girl.</a> <em>BMC Pediatr</em>. 2016 Mar 14; 16:38.</span></li><li><span>Belo SP, Magalhaes AC, Freitas P, Carvalho DM.&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403845/" target="_blank">Familial partial lipodystrophy, Dunnigan variety - challenges for patient care during pregnancy: a case report.</a> <em>BMC Res Notes</em>. 2015 Apr 11; 8:140.</span></li><li><span>Vadrot N, Duband-Goulet I, Cabet E, Attanda W, Barateau A, Vicart P, Gerbal F, Briand N, Vigouroux C, Oldenburg AR, Lund EG, Collas P, Buendina B.&nbsp;<a href="http://hmg.oxfordjournals.org/content/24/7/2096.long" target="_blank">The p.R482W substitution in A-type lamins deregulates SREBP1 activity in Dunnigan-type familial partial lipodystrophy.</a> <em>Hum Mol Genet</em>. 2015 Apr 1; 24(7):2096-109.</span></li><li><span>Diker-Cohen T, Cochran E, Gorden P, Brown RJ.&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422900/" target="_blank">Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.</a> <em>J Clin Endocrinol Metab</em>. 2015 May; 100(5):1802-10.&nbsp;</span></li><!----></ul></div></div></main><!----></div></app-disease-details><!----></div></div><div class="footer"><div class="shrink-width"><div class="footer-links row align-items-center"><div class="col"><a href="/" target="_self">GARD Home</a></div><div class="col"><a href="http://ncats.nih.gov/">NCATS Home</a></div><div class="col"><a href="javascript: void(0)">Site Map</a></div><div class="col"><a href="javascript: void(0)">Browse Glossary A-Z</a></div><div class="col"><a href="javascript: void(0)">Privacy Notice</a></div><div class="col"><a href="javascript: void(0)">Disclaimer</a></div><div class="col"><a href="javascript: void(0)">Accessibility</a></div><div class="col"><a href="javascript: void(0)">FOIA </a></div><div class="col"><a href="javascript: void(0)">OIG</a></div></div><div class="footer-text"><p> If you have problems viewing PDF files, download the latest version of <a target="_blank" href="https://get.adobe.com/reader/" class="footer-links">Adobe Reader</a></p><p> For <a f="http://edi.nih.gov/consulting/language-access-program/about" target="_blank" title="Read the plan" class="ext">language access</a> assistance, contact the <a href="mailto: info@ncats.nih.gov" title="E - mail Public Information Officer" class="footer-links">NCATS Public Information Officer</a></p><p> Genetic and Rare Diseases Information Center (GARD) - PO Box 8126, Gaithersburg, MD 20898-8126 - Toll-free: 1-888-205-2311 </p></div></div></div></app-root>
<script src="runtime.e227d1a0e31cbccbf8ec.js" defer=""></script><script src="polyfills.1aefc75bf7d5acb269d2.js" defer=""></script><script src="main.f870601fdb5bc988c829.js" defer=""></script>
<script id="ScullyIO-transfer-state"></script><script src="js/custom.js"></script>

</body></html>